论文部分内容阅读
目的 探讨前列腺增生症的药物治疗方法。方法应用超选择性α１Ａ受体阻断剂Ｈａｒｎａｌ治疗前列腺增生症６０例。结果 每天 １次０．２ ｍｇ，治疗６ｗ后，患者的ＩＰＳＳ评分、最大尿流率、平均尿流率和残余尿等均明显改善，且无明显副作用。结论超选择α１Ａ 受体阻断剂Ｘａｒｎａｌ是治疗前列腺增生症的理想药物，值得临床推广使用。
Objective To investigate the drug treatment of benign prostatic hyperplasia. Methods Sixty patients with benign prostatic hyperplasia were treated with Harnal, a super-selective α1A receptor antagonist. Results After treated with 0.2 mg once daily for 6 weeks, IPSS score, maximal uroflow rate, mean urinary flow rate and residual urine in patients were significantly improved with no obvious side effects. Conclusion The hyper-selective α1A receptor antagonist Xarnal is an ideal drug for the treatment of benign prostatic hyperplasia and is worthy of clinical promotion.